Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

Corey, Lawrence; B. Gilbert, Peter; Juraska, Michal; C. Montefiori, David; Morris, Lynn; Karuna, Shelly; Edupuganti, Srilatha; Mgodi, Nyaradzo; C. deCamp, Allan; Rudnicki, Erika; Huang, Yunda; Gonzáles, Pedro; Cabello, Robinson; Orrell, Catherine; R. Lama, Javier; Laher, Fatima; Lazarus, Erica; Sánchez, Jorge; Frank, Ian; Hinojosa, Juan; E. Sobieszczyk, Magdalena; Marshall, Kyle; Mukwekwerere, Pamela; Makhema, Joseph; R. Baden, Lindsey; I. Mullins, James; Williamson, Carolyn; Hural, John; Juliana McElrath, M.; Bentley, Carter; Takuva, Simbarashe; M. Gomez Lorenzo, Margarita; Burns, David; Espy, Nicole; K. Randhawa, April; Kochar, Nidhi; Piwowar‐Manning, Estelle; Donnell, Deborah; Sista, Nirupama; Andrew, P.; G. Kublin, James; Gray, Glenda; E. Ledgerwood, Julie; R. Mascola, John; S. Cohen, Myron

doi:10.1056/nejmoa2031738

Public

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

Published in New England Journal of Medicine • Mar 17, 2021

Authors:

Lawrence Corey

Peter B. Gilbert

Michal Juraska

Abstract

BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipient...

Subject

Human immunodeficiency virus (HIV)

Antibody

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!